Rationale for the concept of combined initial therapy im type 2 diabetes mellitus
Diabetes mellitus · 26.07.2026 · 29 (3) · 290-295
DOI: 10.14341/dm13484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes mellitus, online erschienen am 26.07.2026. Verfasst von E. A. Shestakova. Die Arbeit nennt 18 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glycemic targets remain a challenge for most patients with type 2 diabetes (T2D). In many cases, this is due to the patient’s non-compliance with the treatment regimen, insufficient self-monitoring, and delayed intensification of therapy. However, these challenges have been present for many years, and even new classes of antidiabetic drugs have not significantly changed the proportion of individuals with optimal target glycated hemoglobin levels of < 7%. Usually the treatment strategy in T2D patients requires gradual intensification from monotherapy to combination therapy, and afterwards to insulin. However, despite the high proportion of patients who do not achieve target glycemic levels, most patients receive only one medication for the first 5-8 years of treatment. Therefore, there is a need to start T2D therapy with combination of drugs instead of monotherapy. This article provides a rationale for this transition and suggests strategies for implementing it.
Zitieren
APA
Shestakova, E. A. (2026). Rationale for the concept of combined initial therapy im type 2 diabetes mellitus. Diabetes mellitus, 29(3), 290-295. https://doi.org/10.14341/dm13484
Vancouver
Shestakova EA. Rationale for the concept of combined initial therapy im type 2 diabetes mellitus. Diabetes mellitus. 2026;29(3):290-295. doi:10.14341/dm13484
BibTeX
@article{Shestakova2026,
author = {Shestakova, E. A.},
title = {Rationale for the concept of combined initial therapy im type 2 diabetes mellitus},
journal = {Diabetes mellitus},
year = {2026},
volume = {29},
number = {3},
pages = {290--295},
doi = {10.14341/dm13484}
}
EUVIMED